I am not going to tell you anything you already don't know, but would like to give you my perspective. I have been here over a year right here with you brother, but one year is just getting started and comparing to other pharma I have researched lately we are actually moving quite fast. I have been particularly comfortable investing in "tech" stocks over the years and besides a couple large pharma never had real experience in how pharma works and the insane amount of time it takes to develop drugs for human trials.These companies operate at arms length with fed governments and agencies which are notoriously and painfully slow. On top of that we are developing "illegal" medicine which makes things even more difficult. I was frustrated at first and really thought about selling during our fall to .20, but managed to re-read everything and realized if medical marijuana does eventually replace other forms of medicine this is the company to be invested in. Everything about this company is world class and are in good hands here. I really love the fact that they are not dilluters and goal is to eventually score institional funding and merger/jv. Your concerns about not putting out an 8-k with new director appointment and not doing it timely is most likely because it will include another update...safety trial maybe? Here is a paragraph from SEC that answers your questions about the 8-k. Have a wonderful weekend. "In order to live the dream we must first have the dream"
Question 117.05
Question: If a registrant appoints a new executive officer, it may delay disclosure until it makes a public announcement of the event under the Instruction to Item 5.02(c). If the new executive officer were simultaneously appointed to the board of directors of the registrant, would the registrant have to disclose such appointment pursuant to Item 5.02(d) within four business days following such appointment, even if that date is before the public announcement of the officer’s appointment?
Answer: No. In these circumstances, disclosures under paragraph (d) of Item 5.02 may be delayed to the time of public announcement consistent with Item 5.02(c). Similarly, any disclosure required under paragraph (e) of Item 5.02 may be delayed to the time of public announcement consistent with Item 5.02(c). [April 2, 2008]
